Review Article

What is the potential role of hepatic arterial infusion chemotherapy in the current armamentorium against colorectal cancer

Ozkân Kanat, Alexandra Gewirtz, Nancy Kemeny

Memorial Sloan Kettering Cancer Center, GI Medicine, New York, New York, USA

ABSTRACT

The management of colorectal cancer patients with liver metastases is a common clinical problem. If patients can undergo resection of liver metastases, long-term survival can be achieved. Converting a patient from unresectable to resectable, however, remains a major challenge. The majority of patients who undergo liver resection for colorectal metastases recur; therefore, adjuvant treatment following resection should be considered. Emerging literature suggests that hepatic arterial infusion (HAI) can be combined with systemic chemotherapy. Both therapies can be given at nearly full doses, thus improving resectability and outcomes for patients with colorectal liver metastases. HAI plus systemic can also be a useful option for adjuvant treatment after hepatic resection.

KEY WORDS

Liver metastases, colorectal cancer, hepatic arterial infusion, conversion treatment, adjuvant

Introduction

Colorectal cancer (CRC) remains a major health problem in Europe and the United States. In Europe it is a common cancer (436,000 cases, 13.6% of the total) and the second most common cause of cancer-related mortality (212,000 cases, 12.3% of the total) (1). In the United States, CRC is the third most prevalent cancer and was estimated to have caused more than 50,000 deaths in 2010 (2).

The most common site of metastases from CRC is the liver. Approximately 20% of patients with CRC have clinically detectable liver metastases at initial presentation, and at least another 60% of patients will develop liver metastases during their disease course. Despite advances in surgical technique and expanded resectability criteria of liver metastases, radical surgical resection is not possible in 75% to 90% of patients with CRC (3).

Modern systemic chemotherapy regimens with or without biologic agents and liver-directed therapy may result in down staging liver metastases so that resection is possible. In this review, we will summarize the current role of hepatic arterial infusion (HAI) chemotherapy in increasing resection rate and decreasing recurrence after resection for patients with colorectal liver metastases.

Rationale of HAI chemotherapy

Colorectal liver metastases receive their blood supply almost exclusively from the hepatic artery, while blood flow to the normal liver parenchyma is mostly derived from the portal vein. Direct infusion of chemotherapeutic agents with high hepatic extraction via the hepatic artery can achieve prolonged drug exposure to tumor cells at a higher concentration. HAI also permits less exposure of normal liver to the drugs and reduces systemic toxicity.

HAI chemotherapy can be administered by a surgically implantable pump. Before pump placement, patients must have a carefully reviewed arteriogram or computed tomography angiogram to identify any aberrant hepatic anatomy. At the time of pump insertion, surgeons perform a cholecystectomy to prevent chemotherapy-induced cholecystitis. The pump’s catheter is positioned at the junction of the proper and common hepatic arteries and threaded through the gastroduodenal,
or celiac artery. The distal gastroduodenal artery, the right
gastric artery, and small branches supplying the stomach
and duodenum are ligated. The catheter is immobilized in
the artery and the pump is placed in a subcutaneous pocket.
During surgery, the pump is injected with a methylene blue
dye to check for any extrahepatic perfusion. Postoperatively,
a technetium 99m-labeled macroaggregated albumin scan is
performed to confirm the pump’s flow pattern and ensure no
extrahepatic perfusion.

Several different chemotherapeutic agents have been
administered via HAI in the treatment of colorectal liver
metastases (4). Fluorodeoxyuridine (FUDR) is a useful
agent for HAI because of its unique pharmacological
properties. It has a short half-life (<10 minutes) and
extensive first-pass extraction by the liver (94-99%) which
results in an up to 100-400 fold estimated increase in
hepatic exposure (5). In the United States FUDR is used
most often for HAI, whereas 5-Fluorouracil (5-FU) is
used in Europe and Japan (which only yields a 5-10 fold
increase in hepatic exposure). Dexamethasone (20 mg)
can be added with FUDR in order to reduce hepatotoxicity
and increase efficacy (6,7). Irinotecan (20 mg)
has shown some increase in activity which will
be covered in the next section. Using a human tumor colony
forming assay, Kornmann et al. (12) detected significant
concentration-dependent inhibition of colony formation
after a 2 hours exposure to oxaliplatin, suggesting that
patients with colorectal liver metastases may benefit from
HAI with oxaliplatin. Dzodic et al. (13) investigated the
pharmacokinetics of oxaliplatin after intravenous or HAI
administration in a rabbit tumor model. They observed a
significant pharmacokinetic advantage with HAI oxaliplatin
with decreased peak platinum plasma concentrations,
compared to the intravenous route. In addition, HAI of
oxaliplatin showed a higher concentration in liver tumors
(4.3 times that of the concentration found in normal liver
tissue). HAI of oxaliplatin also exhibited a liver extraction
ratio of 0.47 for oxaliplatin administered through the
hepatic artery (14).

**Does the addition of HAI to systemic chemo-
therapy improve results in patients with colorectal liver
metastases? Does it improve resectability?**

Modern systemic chemotherapy has been used to produce
tumor shrinkage allowing subsequent resection in about
15% to 30% of patients with initially unresectable colorectal
liver metastases. Early randomized studies comparing HAI
FUDR with systemic chemotherapy or best supportive care
for CRC liver metastases demonstrated higher response
rates for HAI chemotherapy, with response rates ranging
22% to 62% versus 9% to 25% in patients treated with
systemic chemotherapy (15-24). The majority of the studies
were small or allowed a crossover from systemic to HAI,
so only three studies showed a significant overall survival
benefit with HAI (20,21,24). These studies all used HAI
alone without added systemic chemotherapy.

Available data suggests that HAI FUDR combined
with systemic chemotherapy, including newer agents
such as irinotecan and oxaliplatin, may be a promising
approach to increase response and resectability rates
in both untreated and previously treated patients with
colorectal liver metastases. The combination of HAI and
systemic treatment may also reduce the risk of extrahepatic
progression. Table 1 shows selected studies investigating
the role of HAI plus systemic chemotherapy as conversion
therapy for patients with unresectable colorectal liver
metastases (25-35). HAI FUDR/dexamethasone can be
combined safely and effectively with systemic oxaliplatin
and/or irinotecan-based regimens in this setting. At
MSKCC, 49 patients who had initially unresectable liver
metastases were treated with HAI FUDR/dexamethasone
plus systemic oxaliplatin and irinotecan. Fifty-three percent
of these patients were already treated with systemic therapy;
therefore this therapy was second or third line. Ninety-
two percent of patients had a response (8% complete, and
84% partial) and 47% of the patients were able to undergo
resection (25). Many pre-operative studies do not describe
why patients are unresectable. This study clearly showed
the variables precluding resection: 24% of patients with all
vessels involved, 73% with five or more liver lesions, 98%
with bilobar disease, and 86% with six segments involved.
Ninety percent of patients had a clinical risk score ≥3 (34).
In patients who were chemotherapy naïve (n=23) 57% were
able to undergo liver resection after treatment with HAI
plus systemic therapy. All 23 patients had a response and
the median survival was 50.8 months for these patients (25).
For previously treated patients the response rate was 85%
and the median survival was 35 months.

HAI of oxaliplatin plus systemic 5-FU/LV in patients
with isolated unresectable colorectal liver metastases has been
explored in several studies. Dureux et al. (37) conducted
a phase II study to evaluate concomitant administration of
oxaliplatin via HAI and intravenous 5-FU/LV in 26 patients
with inoperable isolated hepatic metastases from colorectal
carcinoma. The objective response rate was 64% and five
patients were able to undergo liver resection with curative intent. At a median follow-up of 23 months, the median overall and disease-free survival times were 27 and 27 months, respectively. Boige et al. (38) reviewed 87 patients who were treated with HAI oxaliplatin with intravenous 5-FU/LV for isolated unresectable colorectal liver metastases. Although about 79% of patients had previously received either systemic oxaliplatin or irinotecan, the treatment produced an objective response rate of 55%. After treatment, 26% of the patients were operated on with a curative intent. The resection rate was 53% in patients who received HAI as first-line and 19% in patients who received HAI after failure of prior systemic chemotherapy (P=0.008). Five-year overall survival was 56% in the surgery group versus 0% in the nonsurgery group (P<0.0001).

**True Complete Responses**

The use of preoperative HAI along with systemic chemotherapy may increase not only response rates, but also pathological complete response rates (39). In patients treated with systemic chemotherapy alone, Benoist et al. (40) examined 66 metastases that disappeared on helical computed tomography (CT) scans after chemotherapy. Persistent macroscopic disease was observed at surgery in 20 of 66 lesions. Resection of 15 lesions that disappeared showed viable tumor cells in 80%. Of the 31 sites not seen and left in place during surgery, 74% recurred. Therefore, only 17% were true complete responses. In a study from MSKCC, a total of 118 hepatic lesions that disappeared on CT scans after chemotherapy were evaluated. Sixty-eight of these lesions were resected, and 50 were followed clinically (41). Overall, 75 of 118 lesions (64%) were true complete responses, including 44 pathologic and 31 durable clinical complete responses. The true complete responses were more often seen in patients who had received prior HAI (87%) or who had no tumor seen on a magnetic resonance image (75%). The multivariate analysis revealed a significant association between HAI and the true complete responses. In the study by Elias et al (39), patients who received HAI chemotherapy with oxaliplatin were more likely to have a pathological complete response compared with patients who received systemic chemotherapy alone (86% vs. 22%, P<0.02).

The use of HAI in the preoperative setting as first line

### Table 1. Selected trials investigating hepatic arterial infusion plus systemic chemotherapy for unresectable colorectal liver metastases.

<table>
<thead>
<tr>
<th>Ref. No.</th>
<th>Author (year)</th>
<th>No. of Patients</th>
<th>Treatment</th>
<th>RR (%)</th>
<th>Resection rate (%)</th>
<th>Median survival (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>26</td>
<td>Allen-Mersh (2000)</td>
<td>84</td>
<td>HAI FUDR + SYS 5-FU/LV vs. SYS alone</td>
<td>45 vs. 23</td>
<td>N/A</td>
<td>NR</td>
</tr>
<tr>
<td>27</td>
<td>Fallik (2003)</td>
<td>75</td>
<td>HAI pirarubucin SYS 5-FU/LV</td>
<td>34.4</td>
<td>NR</td>
<td>20</td>
</tr>
<tr>
<td>28</td>
<td>Mancini (2003)</td>
<td>123</td>
<td>HAI cisplatin SYS 5-FU</td>
<td>52</td>
<td>NR</td>
<td>18</td>
</tr>
<tr>
<td>29</td>
<td>Shimonov (2005)</td>
<td>23</td>
<td>HAI IRI SYS 5-FU/LV+CARBO</td>
<td>40</td>
<td>NR</td>
<td>N/A</td>
</tr>
<tr>
<td>30</td>
<td>Fiorentini (2006)</td>
<td>76</td>
<td>HAI 5-FU/LV + SYS 5-FU/ LV vs. HAI alone</td>
<td>47.5 vs.41.7</td>
<td>NR°</td>
<td>20 vs.14</td>
</tr>
<tr>
<td>31</td>
<td>Tsutsumi (2008)</td>
<td>16</td>
<td>HAI 5-FU/LV SYS UFT/LV</td>
<td>87.5</td>
<td>NR</td>
<td>22</td>
</tr>
<tr>
<td>32</td>
<td>Idelevich (2009)</td>
<td>21</td>
<td>HAI IRI+5-FU/LV SYS UFT/LV</td>
<td>65</td>
<td>NR</td>
<td>36</td>
</tr>
<tr>
<td>25</td>
<td>Kemeny (2009)</td>
<td>49</td>
<td>HAI FUDR/Dex SYS IRI+OXA</td>
<td>92°</td>
<td>47</td>
<td>Chemo naive 51 Previously treated 35</td>
</tr>
<tr>
<td>33</td>
<td>Goere (2010)</td>
<td>87</td>
<td>HAI OXA + SYS 5-FU/LV</td>
<td>55</td>
<td>26</td>
<td>56% at 5 years</td>
</tr>
</tbody>
</table>

Abbreviations: RR, response rate; HAI, hepatic arterial infusion; FUDR, fluorouridine; SYS, systemic; S-FU, S-Fluorouracil; LV, leucovorin; N/A, not available; NR, not reported; OXA, oxaliplatin; CARBO, carboplatin; IRI, irinotecan; Dex, dexamethasone. °33% of the patients were underwent radiofrequency ablation. "Complete response was seen in 8% of patients.
therapy shows not only statistical improvement in survival but also seems to correlate with pathological response.

**HAI plus systemic chemotherapy in second-line treatment**

Response rates with systemic therapy alone are usually low when given as second-line therapy. Consequently, survival after failing first-line therapy is usually short. In a phase I study at Memorial-Sloan Kettering Cancer Center (MSKCC), the safety of the combination of HAI FUDR and dexamethasone plus systemic irinotecan in 46 patients with unresectable hepatic metastases from CRC was investigated (34). In this series, 40% of the patients had previously received irinotecan and none had received prior oxaliplatin. Although the main objective of the study was to evaluate the toxicity of the combined regimen, the treatment produced a high response rate (74%) and was well tolerated. Eight patients became amenable to hepatic cryosurgery. The median progression-free and overall survivals were 8.1 and 17.2 months for patients who did not undergo cryosurgery. In the group that underwent cryosurgery, median time to progression was 17.3 months. During a median follow-up of 26.4 months after surgery, only one patient died of disease. In another phase I experience using HAI FUDR and dexamethasone along with systemic oxaliplatin combinations (A: oxaliplatin and irinotecan or B: oxaliplatin and 5-FU/LV) in 36 patients with unresectable liver metastases, response and survival were again high (35). In this series, 89% of the patients had received prior chemotherapy, and 69.4% had prior irinotecan. The partial response rates were 90% and 87% for arms A and B, respectively. Seven patients in group A were able to undergo hepatic resection. The median survival time was 35.8 and 22 months for groups A and B, respectively. In a more recent study, the results in Arm A were confirmed. In 49 patients, response rate was 92% with a median survival of 41 months from the time of HAI therapy initiation, even though 53% were previously treated (35).

In a retrospective analysis, Gallagher et al. (42) reported a high partial response rate (44%) with systemic irinotecan plus HAI FUDR/dexamethasone in patients with metastatic CRC to the liver who progressed on oxaliplatin-based chemotherapy. The median survival was 20 months from the start of HAI therapy and 18% of patients were able to undergo surgical resection or ablation.

Administration of newer chemotherapy agents via HAI associated with systemic 5-FU-based therapy may be another approach in this setting. In a phase I study, 21 patients with hepatic metastases from CRC were treated with HAI oxaliplatin plus intravenous 5-FU/LV (43). The treatment regimen, which was administered every 3 weeks, consisted of 5-FU 600 mg/m² and LV 200 mg/m² intravenous combined with 25 mg/m² oxaliplatin HAI with dose increments of 25 mg/m². The limiting toxicities observed at an oxaliplatin dose of 150 mg/m²/cycle were leukopenia, occlusion of the hepatic artery, and acute pancreatitis. The recommended dose was 125 mg/m² every 3 weeks. Overall, 24% of the patients achieved a complete response, with an overall response rate of 59%. The median time to progression had not been reached at the cutoff date, with a median follow-up of 6.7 months. In another phase I-II study conducted by Fiorentini et al. (44), 12 previously-treated (irinotecan, oxaliplatin and/or 5-FU/LV) patients with progressive CRC liver metastases received HAI with oxaliplatin as a 30 minute infusion every 3 weeks. Dose-limiting toxicity was observed at 175 mg/m²/cycle and consisted of occlusion of the hepatic artery, abdominal pain and severe hypotension. Following phase I, all patients were treated with 150 mg/m² for six cycles. The overall response rate was 33% and the median survival was 13 months. In a small study reported by Mancuso et al. (45), patients treated with continuous HAI oxaliplatin (20 mg/m²/day × 5 days) alone showed a response rate of 46%, similar to response rates reported for HAI FUDR as monotherapy. Guthoff et al. (12) reported an overall response rate of 80% for patients treated with HAI using oxaliplatin in combination with 5-FU/LV and mitomycin C.

Boige et al. (38) investigated the activity of HAI oxaliplatin (100 mg/m² over 2 hours) in combination with systemic 5-FU/LV in second-line chemotherapy for colorectal liver metastases previously treated with FOLFIRI (5-FU, LV and irinotecan), FOLFOX (5-FU, LV, and oxaliplatin), or both. They observed a response rate of 62%, which led to R0 resection or radiofrequency ablation in 18% of patients.

A newer prospective study at MSKCC randomized patients to receive Bevacizumab in combination with HAI FUDR and systemic therapy. Of the chemo naïve patients on the non Bev arm, 67% were converted to resectable status. These studies strongly suggest that HAI therapy should be considered as chemotherapy in the second-line treatment of patients with colorectal liver metastases (Table 2). With the addition of HAI, patients are more likely to undergo liver resection even after having failed first-line therapy.

**Is there a role for HAI in adjuvant treatment after hepatic resection?**

Although resection of colorectal liver metastases remains the only curative option, nearly 70% of patients develop recurrence after surgery, which occurs most commonly within two years. Thus, there is a rationale for adjuvant chemotherapy after liver resection. Adjuvant systemic
chemotherapy with 5-FU/LV showed an increase in disease-free but not overall survival (46,47). FOLFIRI did not significantly improve outcomes compared with 5-FU/LV (48). There is no randomized data supporting the use of adjuvant FOLFOX or another oxaliplatin-based chemotherapy after liver resection. In the light of these data the determination of an optimal adjuvant systemic chemotherapy regimen is unclear (49).

Since the majority of recurrences occur in the liver, HAI therapy after liver resection is an option for patients with CRC. Implantation of the HAI pump can be done in conjunction with liver resection. Early randomized studies comparing HAI plus or minus systemic 5-FU-based chemotherapy after liver resection showed that combined therapy significantly improved disease-free survival (50-53). Other studies suggest that modern systemic chemotherapy (i.e., irinotecan and oxaliplatin) and HAI can be safely integrated in order to achieve better overall outcomes (Table 3). In a phase I/II study, HAI FUDR/dexamethasone in combination with intravenous irinotecan after resection of hepatic metastases from CRC was investigated. Treatment was well tolerated and adverse events were manageable. At a median follow-up of 26 months, the 2-year survival was 82% and 2-year PFS was 47%. Additionally promising survival data was reported in a recent phase I study combining HAI FUDR/dexamethasone with systemic oxaliplatin-based chemotherapy in 35 patients with resected liver metastases. Overall survival was 84% at 4 years and progression-free survival was 81% at 1 year, 58% at 2 years, and 50% at 3, 4 and 5 years (55).

In a newer study, 73 patients were treated with HAI FUDR/dexamethasone plus intravenous oxaliplatin- or irinotecan-based regimens with or without bevacizumab after resection of liver metastases (56). Although 48% of the patients had poor prognostic indicators, including 81% of patients with more than one hepatic metastasis, very satisfactory survival results were reported (4-year survival of 85% in no bevacizumab arm and 81% in bevacizumab arm).

In a more recent intergroup trial, HAI FUDR alternating with systemic oxaliplatin and capecitabine was assessed after resection of colorectal liver metastases (57). After a median follow-up of 4.8 years, 55% of the patients recurred. Median time to recurrence was 2.7 years. At 2 years after surgery, 88% of the patients were alive. These promising results prompted the authors to open a larger phase III study comparing capecitabine and oxaliplatin with or without HAI FUDR, but the study was closed early due to poor accrual (58).

House et al. retrospectively analyzed 250 patients who underwent resection of colorectal liver metastases between 2001 and 2005 and received either adjuvant HAI FUDR with systemic chemotherapy (FOLFOX or FOLFIRI), or adjuvant systemic chemotherapy alone. The 5-year liver-recurrence free survival (RFS), overall RFS, and overall survival in the HAI group were 77%, 48%, and 75%, respectively versus 55%, 25%, and 55% in the chemotherapy alone group (P<0.01). The multivariate analysis also revealed adjuvant treatment with HAI and systemic therapy as an independent factor for longer disease free survival (P<0.01) (Accepted for publication in Annals of Surgery, 2011).

### Table 2. Combination of hepatic arterial infusion with newer systemic chemotherapy in the second-line treatment of unresectable liver metastases from colorectal cancer.

<table>
<thead>
<tr>
<th>Ref. No</th>
<th>Author (year)</th>
<th>No. of Patients</th>
<th>1st line</th>
<th>2nd line</th>
<th>RR (%)</th>
<th>Resection rate (%)</th>
<th>Median survival (Months) for all patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>34</td>
<td>Kemeny (2001)</td>
<td>46</td>
<td>5-FU, IRI</td>
<td>HAI FUDR/Dex SYS IRI</td>
<td>74</td>
<td>8</td>
<td>17.2</td>
</tr>
<tr>
<td>35</td>
<td>Kemeny (2005)</td>
<td>36</td>
<td>5-FU, IRI</td>
<td>HAI FUDR/Dex SYS OXA+IRI; OXA+5-FU/LV</td>
<td>90</td>
<td>19.5</td>
<td>35.8</td>
</tr>
<tr>
<td>42</td>
<td>Gallagher (2007)</td>
<td>39</td>
<td>5-FU, OXA, IRI</td>
<td>HAI FUDR/Dex SYS IRI</td>
<td>44</td>
<td>18</td>
<td>20</td>
</tr>
<tr>
<td>38</td>
<td>Boige (2008)</td>
<td>44</td>
<td>5-FU, OXA, IRI</td>
<td>HAI OXA SYS 5-FU/LV</td>
<td>62</td>
<td>18</td>
<td>16</td>
</tr>
</tbody>
</table>

Abbreviations: RR, response rate; 5-FU, 5-fluorouracil; IRI, irinotecan; HAI, hepatic arterial infusion; FUDR, flouxuridine; Dex, dexamethasone; SYS, systemic; OXA, oxaliplatin; LV, leucovorin.
Complications of HAI

The complications of HAI may be technical, drug-related or a combination of both. In 2001, Barnett et al. (59) reviewed 4580 cases that were treated with HAI for colorectal liver metastases. 5-FU and FUDR were the most commonly used drugs for HAI. The most common toxicities were gastrointestinal symptoms (25%), chemical hepatitis (22%), and bone marrow inhibition (9%). The most common catheter-related complications were catheter displacement (7%), hepatic artery occlusion (6%), and catheter thrombosis (5%). The technical complication rates have been shown to drop with increased surgical experience and improvements in pump design. Allen et al. (60) reported on pump complications in 544 patients treated at MSKCC between 1986 and 2001. The overall pump complication rate was 22%. These complications consisted of arterial thrombosis (6%), extrahepatic perfusion (3%), incomplete hepatic perfusion (2%), and hemorrhage (2%). However, the complications during the earlier half of the study period (1986-1993) were significantly higher (25%) than the later half of the study time (1994-2001, 18%, P=0.05). The majority of complications were also salvaged, with 80% of pumps functioning for a minimum of 2 years. Overall pump failure rates were 9% at 1 year and 16% at two years.

Hepatobiliary toxicity is the most serious and dose-limiting complication of HAI. It occurs at a higher incidence with FUDR (61). Elevation of serum transaminase levels is often the first sign of hepatotoxicity. Increases in alkaline phosphatase and bilirubin are more serious and show evidence of more significant hepatic damage. Therefore, changes in liver functions should be monitored regularly during treatment with HAI FUDR. A dose-adjusting algorithm has been devised based on changes in liver function tests (62). Addition of dexamethasone to HAI of FUDR may reduce incidence of bilirubin elevation and also increase the rate of treatment response as demonstrated by Kemeny et al. (6,7). In the adjuvant pump studies at MSKCC, more than twofold increase in alkaline phosphatase levels was observed in 14% to 43% of patients. Total bilirubin elevation > 3.0 mg/dL was seen in 0 to 19%, and biliary stents were placed in 0 to 8%. A higher incidence of biliary toxicity was seen in the study where FUDR dose was 0.14 (as compared to 0.12 in the newer studies). In a new study that was recently published in JCO, patients were randomized to receive Bev versus no Bev in addition to HAI FUDR or FOLFIRI. In the group that received Bev, bilirubin ≥ 3 mg/dL was seen in 5 of 35 versus zero of 38 patients (P=0.02) and biliary stents were placed in four versus zero patients (P=0.05). This study was terminated early due to biliary toxicity.

Biliary sclerosis is not observed with HAI of 5-FU (59) which tends to associate more with increased risk of myelosupression (59). Therefore, one logical approach to reduce biliary toxicity is to alternate between HAI FUDR and HAI 5-FU. Davidson et al. (63) used HAI FUDR at a dose of 0.1 mg/kg/day for seven days followed by HAI

### Table 3. Adjuvant therapy with hepatic arterial infusion plus newer chemotherapy agent after resection of colorectal liver metastases.

<table>
<thead>
<tr>
<th>Ref. No</th>
<th>Author (year)</th>
<th>No. of Patients</th>
<th>Treatment</th>
<th>DFS</th>
<th>OS</th>
</tr>
</thead>
<tbody>
<tr>
<td>54</td>
<td>Kemeny (2003)</td>
<td>96</td>
<td>HAI FUDR/Dex SYS IRI</td>
<td>47% 2 years</td>
<td>89% 2 years</td>
</tr>
<tr>
<td>55</td>
<td>Kemeny (2009)</td>
<td>35</td>
<td>HAI FUDR/Dex SYS OXA+5-FU/LV</td>
<td>88% 3 years</td>
<td>88% 3 years</td>
</tr>
<tr>
<td>56</td>
<td>House (2009)</td>
<td>250</td>
<td>HAI FUDR/Dex+ SYS OXA+5-FU/LV or IRI+5-FU/LV vs SYS alone no HAI</td>
<td>48% 5 years</td>
<td>77% 5 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>25% 5 years</td>
<td>55% 5 years</td>
</tr>
<tr>
<td>57</td>
<td>Alberts (2010)</td>
<td>76</td>
<td>HAI FUDR/Dex SYS OXA+CAP</td>
<td>32.7 mo</td>
<td>88% 2 years</td>
</tr>
<tr>
<td>58</td>
<td>Kemeny (2011)</td>
<td>73</td>
<td>HAI FUDR/Dex SYS no Bevacizumab</td>
<td>46% 4 years</td>
<td>85% 4 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>HAI FUDR/Dex SYS no Bevacizumab vs SYS OXA+CAP</td>
<td>46% 4 years</td>
<td>85% 4 years</td>
</tr>
</tbody>
</table>

Abbreviations: HAI, hepatic arterial infusion; FUDR, flouxuridine; Dex, dexamethasone; SYS, systemic; IRI, irinotecan; mo, months; OS, overall survival; DFS, disease-free survival; OXA, oxaliplatin; 5-FU, 5-Fluorouracil; LV, leucovorin; CAP, capecitabine. *Accepted for publication in Annals of Surgery, 2011. *Retrospective; Median.
boluses of 5-FU 15 mg/kg on days 14, 21, and 28. With this schedule, 12 (21%) patients had temporary liver enzyme elevations and only 2 patients (3.5%) developed biliary sclerosis. In another study, HAI FUDR was administered for seven days, and HAI 5-FU bolus was given on days 15, 22 and 29, with the cycle repeated every 35 days. None of the patients in this study had treatment terminated because of hepatobiliary toxicity (64).

Conclusions

Available data and literature demonstrates that HAI may have a definitive role in successful treatment of patients with hepatic metastases from CRC. HAI can be combined safely and effectively with modern systemic chemotherapy in neoadjuvant (conversion therapy), second-line and adjuvant treatment of selected patients. On the other hand, concerns about technical problems and potential toxicity of the treatment may discourage oncologists from using HAI. However, improvement in surgical techniques and the development of modern implantable pumps have decreased technical complications and improved patient tolerability of treatment. Alternative treatment modalities are needed to increase survival rates for patients with colorectal liver metastases. The use of HAI in conjunction with systemic chemotherapy seems to be a promising approach for these patients. Further large prospective randomized studies could clarify the exact role of HAI for neoadjuvant, second-line or adjuvant treatment of colorectal liver metastases.

References


